Dr. John Hurrell joined Ferghana in 2013 as Strategic Transaction Advisor, Diagnostics/Tools Sector, to augment the firm’s scientific expertise.
John was recently Senior Executive Vice President of Seegene [Seoul, Korea], where he was responsible for global licensing, OEM, and companion diagnostic deals. John has a distinguished track record of growing companies in the healthcare industry, including the Focus Diagnostics product subsidiary of Quest Diagnostics. At Focus, he was the president and general manager where he led the development and launch of more than 70 molecular diagnostic tests and successfully gained 510(k) approvals for six products. Previously, John served as VP of Business Development at Quest Diagnostics. He also held numerous management positions at several healthcare firms, including SVP and General Manager positions at TriPath Oncology, a subsidiary of TriPath Imaging, which was acquired by Becton Dickinson and Company.
John is a Harvard Medical School Fulbright Fellow (monoclonal antibody technologies) and has a PhD in Biochemistry/Immunology and a Bachelor of Science in Biochemistry/Chemistry from Melbourne University.